Asia Innovators: Singapore's Inviragen In Race With Sinovac For HFMD Vaccine
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Inviragen (Singapore) Pte Ltd is recruiting patients for its Phase I clinical trial in Singapore for its hand, foot and mouth disease vaccine INV21
You may also be interested in...
Inviragen Finds New Life For Shelved Japanese Encephalitis Vaccine At State-Owned VABIOTECH
A vaccine project put on the shelf – after better-funded Intercell won regulatory approval for a rival product – has found a new home in Vietnam at a state-owned company looking to keep costs in check.
WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)
China's major players rack up double-digit growth in the second quarter, with WuXi PharmaTech celebrating its first $100 million quarter and Sinovac seeing a 50% increase in revenues. On the heels of the NovaMed acquisition, SciClone Pharmaceuticals Inc. is preparing to enter more markets in China and anticipates price cuts for its flagship product Zadaxin. In a recurring feature, PharmAsia News combs through earnings calls to bring readers the highlights in the critical emerging markets.
WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)
China's major players rack up double-digit growth in the second quarter, with WuXi PharmaTech celebrating its first $100 million quarter and Sinovac seeing a 50% increase in revenues. On the heels of the NovaMed acquisition, SciClone Pharmaceuticals Inc. is preparing to enter more markets in China and anticipates price cuts for its flagship product Zadaxin. In a recurring feature, PharmAsia News combs through earnings calls to bring readers the highlights in the critical emerging markets.